BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37642071)

  • 1. Programmed Death 1 (PD-1) Expression in Relapsing and Remitting Hodgkin Lymphoma as Prognostic Factor.
    Bouzari B; Basi A; Dadkhah S; Panahi M; Mohammadi S
    Asian Pac J Cancer Prev; 2023 Aug; 24(8):2829-2835. PubMed ID: 37642071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.
    Dilly-Feldis M; Aladjidi N; Refait JK; Parrens M; Ducassou S; Rullier A
    Pediatr Blood Cancer; 2019 May; 66(5):e27571. PubMed ID: 30637917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
    Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
    Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients.
    Antel K; Chetty D; Oosthuizen J; Mohamed Z; Van der Vyver L; Verburgh E
    Pathology; 2021 Aug; 53(5):628-634. PubMed ID: 33558066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
    BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma.
    Cuccaro A; Bellesi S; Galli E; Zangrilli I; Corrente F; Cupelli E; Fatone F; Maiolo E; Alma E; Viscovo M; D'Alò F; Annunziata S; Martini M; Rufini V; Giordano A; De Stefano V; Larocca LM; Hohaus S
    J Leukoc Biol; 2022 Sep; 112(3):539-545. PubMed ID: 35060170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death ligand 1 expression in diffuse large B cell lymphoma: correlation with clinicopathological prognostic factors.
    Ibrahim EM; Refat S; El-Ashwah S; Fahmi MW; Ibrahiem AT
    J Egypt Natl Canc Inst; 2023 May; 35(1):12. PubMed ID: 37150782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases.
    Kubes V; Kren L; Sokol F; Michalka J; Muzik J; Arpas T; Krenova Z; Kral Z
    In Vivo; 2023; 37(4):1735-1742. PubMed ID: 37369476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
    Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
    Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of clinical factors and immunocheckpoint molecules in the prognosis of patients with supratentorial extraventricular ependymoma: a single-center retrospective study.
    Wang L; Han S; Yan C; Yang Y; Li Z; Yang Z
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1259-1270. PubMed ID: 33387039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.
    Ozturk V; Yikilmaz AS; Kilicarslan A; Bakanay SM; Akinci S; Dilek İ
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e375-e381. PubMed ID: 32295735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
    El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
    Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
    Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
    J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.
    Volaric A; Bacchi CE; Gru AA
    Am J Surg Pathol; 2020 Oct; 44(10):1353-1366. PubMed ID: 32649320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of PD-1/PD-L1 in peripheral blood and tumor tissues of patients with classical Hodgkin's lymphoma.
    Feng X; Luo X; Yang Y; Fan Y; Ye Q
    Medicine (Baltimore); 2023 Nov; 102(44):e35757. PubMed ID: 37933048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of Expression of PD-1 and PD-L1 In Head And Neck Squamous Cell Carcinoma And their Association With Nodal Metastasis: A Cross-Sectional Study.
    Malik IS; Asif M; Bashir N; Ara N; Rashid F; Din HU; Malik NS; Bashir A
    Asian Pac J Cancer Prev; 2022 Feb; 23(2):467-473. PubMed ID: 35225458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.